Biodistribution of [11C]laniquidar in healthy volunteers.

Biodistribution and dosimetry of the newly developed P-gp PET tracer [11C]laniquidar in healthy volunteers.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25649

Enrollment

Registered

2010-09-15

Start date

2010-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biodistribution, dosimetry, healthy volunteers

Interventions

1x[ 11C]Laniquidar whole-body PET-low-dose CT scan. A low-dose whole-body CT scan is performed after which a single dose of 370MBq [11C]Laniquidar is venously injected. At the same time a whole-body

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-65 years; 2. Good physical health evaluated by medical history, physical (including neurological) examination and screening laboratory tests; 3. Written informed consent of each subject.

Exclusion criteria

Exclusion criteria: 1. Any clinical significant abnormality of any clinical laboratory test; 2. Any subject who has received any investigational medication within 30 days prior to the start of this study, or who is scheduled to receive an investigational drug; 3. Major psychiatric or neurological disorder; 4. History of alcohol and/or drug abuse (DSM-IV criteria); 5. History of coagulation problems; 6. Any sign of cardiovascular disease; 7. Current use of any medication, other than contraceptive medication; 8. Breast feeding; 9. Pregnancy; 10. Unable to understand or read the Dutch language.

Design outcomes

Primary

Measure	Time frame
Biodistribution and dosimetry of [11C]Laniquidar in healthy volunteers.	—

Secondary

Measure	Time frame
Metabolic profile of [11C]Laniquidar in humans.	—

Contacts

Public ContactE.A.M. Froklage

P.O.Box 7057

f.froklage@vumc.nl+31 (0)20 4445214

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)